Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the Glioblastoma (GBM) patients in the backdrop of mutational status of EGFR and PTEN genes.

CONCLUSIONS: We conclude EGFR gene alterations with wildtype PTEN is associated with significantly better PFS and OS in patients treated with antityrosine kinase inhibitors (Gefitinib). Combined EGFR and PTEN gene mutation is associated with significantly poor response to Geftinib in terms of Median OS. PMID: 29444555 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgical Sciences - Category: Neurosurgery Tags: J Neurosurg Sci Source Type: research